Preventive Intake of a Multiple Micronutrient Supplement during Mild, Acute SARS-CoV-2 Infection to Reduce the Post-Acute COVID-19 Condition : A Double-Blind, Placebo-Controlled, Randomized Clinical Trial
Tomasa-Irriguible, Teresa Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Monfà, Ramon (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Miranda-Jiménez, Cristina (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Morros, Rosa (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Robert, Neus (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Bordeje, Mª Luisa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Vidal, Sandra (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Torán Monserrat, Pere (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Barriocanal, Ana María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)

Data:	2024
Resum:	Patients hospitalized with COVID-19 have low levels of vitamins and trace elements. This could lead to a post-acute COVID-19 condition (PCC) that can worsen a patient's quality of life. We aimed to study the baseline micronutrient status of patients and assess whether a multiple micronutrient supplement (MMS) taken for 2 weeks at the first sign of COVID-19 symptoms would be able to reduce the incidence of PCC. This double-blind, placebo-controlled, randomized clinical trial was conducted in adult outpatients with acute COVID-19, recruited between 2021 and 2023 in Spain. Of the 285 patients assessed for eligibility, 267 were randomized and 246 were included in the intent-to-treat population. The mean age was 46. 8 years, and 68% were female. Overall, 54. 6% had micronutrient deficiencies in the acute phase of COVID-19 at baseline, and 26. 2% had PCC after 180 days of follow-up (D180). The most frequently recorded PCC symptoms were neurological (14. 1%), with 24% patients scoring worse in the cognitive tests compared to their baseline status. The rate of PCC at D180 was similar between the placebo (25. 0%) and intervention (27. 7%) groups, without significant differences (p = 0. 785). Age over 50 years was the most relevant risk factor for developing PCC, followed by female sex. The most important protective factor against PCC was SARS-CoV-2 vaccination. In this population of predominantly middle-aged, white women with acute COVID-19 not requiring hospital admission, MMS intake for 14 days at symptom onset did not prevent PCC nor improve their micronutrient status at D180.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	COVID-19 ; SARS-CoV-2 ; Post-COVID-19 condition ; Long COVID ; Nutritional status ; Micronutrients ; Multiple micronutrient supplement ; Cognitive assessment ; Cognitive impairment ; Quality of life
Publicat a:	Nutrients, Vol. 16 Núm. 11 (May 2024) , ISSN 2072-6643

DOI: 10.3390/nu16111631
PMID: 38892564

19 p, 835.9 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats